- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:46 | Character Biosciences raises $93M with an eye on vision loss drugs | ||
| Mo | Verve gets FDA green light to expand base editing trial into US | ||
| Mo | 23andMe files for bankruptcy as CEO Anne Wojcicki resigns | ||
| Mo | Novo adds to obesity drug pipeline via $200M deal with China-based biotech | ||
| Mo | Biogen plots new global headquarters in Kendall Square | ||
| Mo | Tempero Bio gets $70M to advance substance abuse treatment | ||
| Mo | Accelerate oncology drug development: A data-driven approach to clinical decisions | ||
| Mo | Leveraging clinical and financial data sets to guide investment strategies in 2025's biopharma market | ||
| Fr | Optum Rx is reforming how it pays pharmacies | ||
| Fr | Delayed CDC meeting on vaccines is rescheduled to April | ||
| Fr | AstraZeneca deepens China investment; Editas loses CFO to Dyne | ||
| Fr | J&J boosts US manufacturing as big pharma reshores | ||
| Fr | Alnylam prices heart drug at premium to rivals | ||
| Do | Alnylam drug gets long-awaited FDA approval in deadly heart disease | ||
| Do | Novartis builds case for new SMA gene therapy | ||
| Do | Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease | ||
| Mi | Optum Rx says it will eliminate some prior authorization requirements | ||
| Mi | Immunovant claims study success for immune disease drug but holds off on submission | ||
| Mi | Cargo shelves cell therapy research and lays off almost all staff | ||
| 18.03. | Sofinnova's latest biotech fund sprouts three new startups | ||
| 18.03. | Prime sets sights on liver, lung disease as next target for its gene editing tech | ||
| 18.03. | Stoke CEO exits; Medicare drug price talks advance | ||
| 18.03. | Duchenne patient dies after receiving Sarepta gene therapy | ||
| 18.03. | Arbor raises $74M amid genetic medicine's funding slump | ||
| 17.03. | Taiho buys Swiss biotech and its ADC tech for $400M |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
